Acidic and basic fibroblast growth factors (FGFs) are members of a family of multifunctional polypeptide growth factors that stimulate proliferation of cells of mesenchymal, epithelial and neuroectodermal origin. Like other growth factors, FGFs act by binding and activating specific cell surface receptors. These include the Flg receptor or FGFR-1, the Bek receptor (or FGFR-2), FGFR-3, FGFR-4, FGFR-5 and FGFR-6. These receptors usually contain an extracellular ligand-binding region containing three immunoglobulin-like domains, a transmembrane domain and a cytoplasmic tyrosine kinase domain. The gene encoding human Bek (also designated K-sam) maps to chromosome 10q26.13 and is alternatively spliced to produce several isoforms. Heterogeneous mutations in Bek are associated with a range of craniosynostosis syndromes including Pfeiffer syndrome, Crouzon syndrome, Jackson-Weiss syndrome and Apert syndrome..
Background References
1. Ramsey MR et al. FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma. J Clin Invest 123:3525-38 (2013).
2. Huang Y et al. Twist1- and twist2-haploinsufficiency results in reduced bone formation. PLoS One 9:e99331 (2014).
Sequence Similarity
Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.
Post-translational Modification
Autophosphorylated. Binding of FGF family members together with heparan sulfate proteoglycan or heparin promotes receptor dimerization and autophosphorylation on several tyrosine residues. Autophosphorylation occurs in trans between the two FGFR molecules present in the dimer. Phosphorylation at Tyr-769 is essential for interaction with PLCG1.; N-glycosylated in the endoplasmic reticulum. The N-glycan chains undergo further maturation to an Endo H-resistant form in the Golgi apparatus.; Ubiquitinated. FGFR2 is rapidly ubiquitinated after autophosphorylation, leading to internalization and degradation. Subject to degradation both in lysosomes and by the proteasome.
Western blot analysis of FGFR2 on different lysates with Rabbit anti-FGFR2 antibody (ET1703-78) at 1/1,000 dilution.
Lane 1: HT-29 cell lysate (20 µg/Lane) Lane 2: HaCaT cell lysate (20 µg/Lane) Lane 3: PC-12 cell lysate (20 µg/Lane) Lane 4: L6 cell lysate (20 µg/Lane) Lane 5: Mouse brain tissue lysate (40 µg/Lane) Lane 6: Rat brain tissue lysate (40 µg/Lane)
Predicted band size: 92 kDa Observed band size: 145 kDa
Exposure time: Lane 1-4: 1 minute 18 seconds; Lane 5-6: 6 seconds; ECL: K1801;
4-20% SDS-PAGE gel.
Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody (ET1703-78) at 1/1,000 dilution was used in 5% NFDM/TBST at 4℃ overnight. Goat Anti-Rabbit IgG - HRP Secondary Antibody (HA1001) at 1/50,000 dilution was used for 1 hour at room temperature.
Western blot analysis of FGFR2 on different lysates with Rabbit anti-FGFR2 antibody (ET1703-78) at 1/1,000 dilution.
Lane 1: MCF7 cell lysate (10 µg/Lane) Lane 2: NIH/3T3 cell lysate (10 µg/Lane) Lane 3: Mouse brain tissue lysate (20 µg/Lane)
Predicted band size: 92 kDa Observed band size: 145 kDa
Exposure time: 1 minute; ECL: K1801;
4-20% SDS-PAGE gel.
Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody (ET1703-78) at 1/1,000 dilution was used in 5% NFDM/TBST at 4℃ overnight. Goat Anti-Rabbit IgG - HRP Secondary Antibody (HA1001) at 1/50,000 dilution was used for 1 hour at room temperature.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"